Clinical Trial

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well pembrolizumab given every 12 weeks works compared to every 3 weeks in treating patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab every 12 weeks may provide similar disease control with fewer treatments for patients with non-small cell lung cancer when compared to every 3 weeks. Demonstrating that 12 week dosing is as effective as 3 week dosing may also have a significant impact when considering the cost required for these medications.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2019-07-19; most recent amendment 2026-05-13.
Status change: Recruiting → Active, Not Recruiting 2023-01-27
Status change: Not Yet Recruiting → Recruiting 2020-02-14
Trial Details
NCT Number NCT04032418
Lead Sponsor Roswell Park Cancer Institute
Conditions Lung Non-Small Cell Carcinoma
Enrollment 9 participants
Start Date 2020-08-13
Primary Completion 2025-03-14 (estimated)
Study Completion 2026-06-14 (estimated)
Updated on ClinicalTrials.gov 2026-05-18